The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them
- 20 August 2020
- journal article
- review article
- Published by Springer Nature in Applied Microbiology and Biotechnology
- Vol. 104 (19) , 8231-8242
Abstract
Oncolytic virus (OV) immunotherapy is characterized by viruses which specifically target cancer cells and cause their cytolysis. They provide a unique and promising new tool for the eradication of cancer as they interact with and affect the tumor microenvironment (TME), vasculature, and immune system. Advancements of genetic engineering have allowed for these viruses to be armed in such a way to have enhanced targeting, strong immunomodulation properties, and an ability to modify the TME. However, there are still major limitations in their use, mostly due to difficulties in delivering the viral particles to the tumors and in ensuring that the immunomodulatory properties are able to stimulate the host immune response to mount a complete response. Using novel delivery systems and using OVs as a complementary therapy in a combinatorial treatment have shown some significant successes. In this review, we discuss the major issues and difficulties in using OVs as anti-tumor agents and some of the strategies put in place so far to overcome these limitations. Key points • Oncolytic viruses (OVs) infect cancer cells and cause their cytolysis. • The major limitations in using OVs as anti-tumor therapy were discussed. • The potential strategies to overcome these limitations were summarized.Keywords
Funding Information
- Zhejiang Provincial Natural Science Foundation of China (LY17H160062)
- Zhejiang Provincial Medical and Healthy Science and Technology Projects (WKJ-ZJ-1710, 2019KY248)
- Zhejiang Provincial Science and Technology Projects (LGF19H160026)
- National Natural Science Foundation of China (81672430, 81602706)
This publication has 56 references indexed in Scilit:
- Updates to the antitumor mechanism of oncolytic virusThoracic Cancer, 2019
- Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic VirusesStem Cells, 2019
- Armed oncolytic viruses: A kick-start for anti-tumor immunityCytokine & Growth Factor Reviews, 2018
- Oncolytic Virotherapy versus Cancer Stem Cells: A Review of Approaches and MechanismsCancers, 2018
- Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9Oncotarget, 2017
- Long‐term treatment with the oncolytic ECHO‐7 virus Rigvir of a melanoma stage IV M1c patient, a small cell lung cancer stage IIIA patient, and a histiocytic sarcoma stage IV patient‐three case reportsAPMIS, 2016
- An Oncolytic Adenovirus Enhanced for Toll-like Receptor 9 Stimulation Increases Antitumor Immune Responses and Tumor ClearanceMolecular Therapy, 2012
- Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cellsCancer Gene Therapy, 2009
- Chemical control of protein stability and function in living miceNature Medicine, 2008
- Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.Proceedings of the National Academy of Sciences, 1993